First report of vancomycin-resistant Enterococcus faecium isolated in Poland  by Hryniewicz, W. et al.
Concise  C o m m u n i c a t i o n s  5 0 3  
relation to antibiotic susceptibility. J Clin Microbiol 1982; 16: 
458-63. 
21. Voutsinas D, Mavroudis TH, Avlamis A, Giomarellou H. In vitro 
activity of meropenem, a new carbapenem, against niultiresistant 
Pseudomonas aeruginora compared with that of other antipseudo- 
monal antimcrobials. J Antimicrob Chemother 1989; Suppl24: 
143-7. 
22. Perez FJ, Cimeno C, Navarro 11, Garcia De Lomas J. Mero- 
penem permeation through the outer membrane of Pseudomonas 
aeruginosa can involve pathways other than OprD porin channel. 
Chemotherapy 1996; 42: 210-14. 
23. Masuda N, Sakagawa E, Ohya S. Outer membrane proteins 
responsible for multiple drug resistance in Pseudomonas aemginora. 
Antimcrob Agents Chemother 1995; 39: 645-9. 
First report of vancomycin-resistant Enterococcus fuecium isolated in Poland 
Clin h4icrohiol Infict 1999; 5: 503-505 
W Hryl.ziewiczl*, K. Szczypa', M.  Bronk', A. Satnet', A. Hellmatin' and K. Ezdnski' 
'Sera and Vaccines Central Research Laboratory, Chelmska 30/34, 00-725, Warsaw, 'Department 
of Clinical Bacteriology Clinical Hospital No. 1, 3Hematology Ward of Gdansk Medical University, 
Gdansk, Poland 
*Tel: +48 22 841 33 67 Fax: +48 22 841 29 49 
E-mail: waleria@urania.il.waw.pl 
Accepted 5 January 1999 
During the last decade, Enterococcars has evolved as one 
of the most significant nosocomial pathogens, parti- 
cularly as an etiologic agent of nosocomial bloodstream 
infections [1,3]. The increase in incidence of entero- 
coccal infections is a consequence of their broad natural 
and acquired resistance to antimicrobial agents, several 
different reservoirs ofresistant strains, and, in particular, 
the acquisition of resistance to the glycopeptides, some- 
times leaving no therapeutic options in seriously ill 
patients [3]. 
The first clinical isolates of vancomycin-resistant 
enterococci (VRE) were dlscovered in 1986 by Leclercq 
et a l  in France [4] and by Uttley et a1 in the UK [5]. 
Both outbreaks involved both Enterococcus faecalis and 
E. faecium, and the strains demonstrated high-level 
resistance to vancomycin and teicoplanin. 
Four phenotypes of vancomycin resistance, VanA, 
VanB, VanC and VanD, have been reported. Genes 
determining the VanA and VanB phenotypes are usually 
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Figure 1 RAPD products obtained in  PCR reactions using ERIC1, AP4 and ERICl/AP4 primers. Molecular size markers 
are indicated (Si, h/BstEII; S2, pBR 322/hhpI). Lane 1, isolate 1 (1639); lane 2, isolate 2 (1640); lane 3, isolate 3 (1641). 
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Figure 2 Pulsed-field gel electrophoresis of BglII-digested 
chromosomal DNA from E. faecitrrn isolates. Molecular 
masses (in kilobases) were obtained from bacteriophage 
DNA concatamers (S). Lane 1, isolate 1 (1639); lane 2, 
isolate 2 (1640); lane 3, isolate 3 (1641). 
and their expression is inducible. The VanC type of 
resistance is a natural feature of E. gallinarum and E. 
casselijlavur. Recently, a new glycopeptide resistance 
phenotype, VanD, was described in E. faecium [6-81. 
There were no  reports of VRE in Poland up to the 
end of 1996, when the first strain was isolated from the 
urinary tract of a patient on the hematology ward of 
Gdansk Medical University (data not published). At 
the beginning of 1997, VRE were isolated from three 
patients hospitalized in the same department. The pre- 
sent paper describes characteristics of these first isolates. 
Two of the patients suffered from acute myelo- 
blastic leukemia, and one from chronic myeloblastic 
leukemia. All three received multiple courses of anti- 
biotics, including glycopeptides, as a result of several 
febrile episodes. In two of the cases, VRE were isolated 
from blood, feces and vaginal swabs (the latter two 
indicating colonization). The third patient was only 
colonized with VRE in the gastrointestinal tract (stool 
specimen positive for VRE). 
The isolates were first identified as vancomycin- 
resistant E. faecium in the Department of Clinical 
Bacteriology, Clinical Hospital No. 1 in Gdansk and 
were sent to the National Reference Center for Anti- 
biotic Resistance in Bacteria in the Sera and Vaccines 
Central Research Laboratory for further investigation. 
Identification to the genus level was carried out 
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Figure 3 Products of specific PCR amplification of vanA 
gene. Molecular size markers are indicated. (Sl, h/BstEII; 
SZ, pBR 322/MspI). Lane 1, glycopeptide-susceptible E. 
faecitrrn BM4147-1; lane 2, glycopeptide-resistant 
E.faen'urn BM4147; lane 3, isolate 1 (1639); lane 4, isolate 
2 (1640); lane 5, isolate 3 (1641). 
according to the criteria of Facklam and Collins [9], 
and the species were identified using the rapid ID32 
Strep system (bioMtrieux, Marcy I'Etoile, France). All 
isolates were confirmed to be E. faecium. 
Minimum inhibitory concentrations (MICs) were 
determined by a standard agar dilution procedure 
according to the criteria recommended by the National 
Committee for Clinical Laboratory Standards (NCCLS) 
[lo]. The antimicrobial agents tested were penicillin, 
ampicillin, chloramphenicol, ciprofloxacin, tetracycline, 
streptomycin, gentamicin, vancomycin and teicoplanin. 
The results of the susceptibility testing are listed in 
Table 1. 
The presence of van genes was detected by PCR 
with primers specific for vanA, vanB and vanC genes 
[11,12]. The vunA gene was identified in all strains 
analyzed (Figure 1). The isolates were typed by 
Table 1 Minimal inhibitory concentrations (MICs) (mg/L) 
of three vancomycin-resistant Enterococcus strains 
Isolate 1 Isolate 2 Isolate 3 
Antibiotics (1639) (1 640) (1641) 
~ 
PeniciUln 2512 128 256 
Ampicdin 2256 32 2256 
Tetracycline 0.25 64 64 
Streptomycin 1024 22048 22048 
Gentamcin 16 2048 2048 
Ciprofloxacin 128 128 128 
Teicoplamn 32 64 16 
Vancomycin 256 512 256 
Chloramphenicol 4 8 4 
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genomic DNA restriction fragment length poly- 
morphism (RFLP) analysis using SmaI restriction 
enzyme and a CHEF DRII (BioRad) apparatus for 
PFGE [I?] and by randomly amplified polymorphic 
DNA (RAPD) analysis using ERIC1 and AP4 primers 
[13] (Figures 2 and 3). 
All three E. faecium isolates were found to harbor 
the vanA gene but were genetically unrelated as shown 
by both PFGE (with greater than six bands difference) 
and RAPD (different patterns). Further studies are 
needed in order to identify the source of VRE and the 
routes of their spread among patients. Broad infection 
control measures were proposed for implementation in 
the hospital to limit the spread of VRE. 
It is well known that enterococci constitute a large 
reservoir of resistance genes. This first report of VRE 
in Poland may indicate the potential risk of transferring 
high-level vancomycin resistance to other more virulent 
nosocomial pathogens, thus calling for more stringent 
control over antibiotic usage and for careful monitoring 
of this emerging resistance among enterococci in our 
country. 
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